EGFR and non-small cell lung carcinoma: A previous study demonstrated that body surface area (BSA) influenced gefitinib efficacy in patients with advanced NSCLC who harbored EGFR mutations [13, 14], although contrary reports finding no effect of BSA also exist [15].